Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study).
R BissonnetteT LugerD ThaçiD TothA LacombeS XiaR MazurM PatekarP CharefM MilutinovicC LeonardiUlrich MrowietzPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2018)
Secukinumab 300 mg treatment delivered high and sustained levels of skin clearance and improved quality of life through 5 years in patients with moderate-to-severe psoriasis. Favourable safety established in the secukinumab phase 2/3 programme was maintained through 5 years.